"Saint Mary’s is 1 in 175 hospitals in the world to receive the Pathway to Excellence distinction. A Pathway to Excellence organization is committed to providing a positive workplace environment where employees excel and feel valued as integral members of interprofessional health care teams. This designation confirms to the public that employees working at Saint Mary’s know their efforts are supported. The honor encourages other employees to join their colleagues in this desirable and nurturing environment."

During the past decade, Saint Mary's Regional Medical Center conducted 132 clinical trials. In the 10-year time frame, 132 clinical trials started and 50 clinical trials were completed, i.e. on average, 37.9% percent of trials that started reached the finish line to date. In the past 5 years, 47 clinical trials started and 41 clinical trials were completed. i.e. 87.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Mary's Regional Medical Center" #1 sponsor was "National Cancer Institute (NCI)" with 71 trials, followed by "SWOG Cancer Research Network" with 30 trials sponsored, "Alliance for Clinical Trials in Oncology" with 24 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 12 trials sponsored and "NRG Oncology" with 12 trials sponsored. Other sponsors include 15 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Mary's Regional Medical Center" #1 collaborator was "National Cancer Institute (NCI)" with 85 trials as a collaborator, "NRG Oncology" with 10 trials as a collaborator, "Canadian Cancer Trials Group" with 9 trials as a collaborator, "Cancer and Leukemia Group B" with 2 trials as a collaborator and "Genentech, Inc." with 2 trials as a collaborator. Other collaborators include 16 different institutions and companies that were collaborators in the rest 23 trials.

According to Clinical.Site data, the most researched conditions in "Saint Mary's Regional Medical Center" are "Recurrent Squamous Cell Lung Carcinoma" (10 trials), "Invasive Breast Carcinoma" (8 trials), "Stage IV Squamous Cell Lung Carcinoma AJCC v7" (8 trials), "Stage IV Lung Cancer AJCC v8" (6 trials) and "Recurrent Lung Non-Small Cell Carcinoma" (5 trials). Many other conditions were trialed in "Saint Mary's Regional Medical Center" in a lesser frequency.

Most popular intervention types in "Saint Mary's Regional Medical Center" are "Drug" (123 trials), "Other" (92 trials), "Biological" (67 trials), "Procedure" (48 trials) and "Radiation" (34 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (43 trials), "Quality-of-Life Assessment" (39 trials), "Computed Tomography" (29 trials), "Biospecimen Collection" (27 trials) and "Nivolumab" (24 trials). Other intervention names were less common.

The vast majority of trials in "Saint Mary's Regional Medical Center" are 136 trials for "All" genders, 21 trials for "Female" genders and 5 trials for "Male" genders.

Currently, there are NaN active trials in "Saint Mary's Regional Medical Center". undefined are not yet recruiting, 47 are recruiting, 73 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 25 completed trials in Saint Mary's Regional Medical Center, 6 suspended trials, and 7 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Mary's Regional Medical Center, 3 "Phase 1" clinical trials were conducted, 75 "Phase 2" clinical trials and 85 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 7 trials that are defined as “Not Applicable".